Technology transfer / Localization · MENA · Announced 6 Mar 2025

Sandoz → SEDICO

Sandoz agreed to transfer full manufacturing technology for five oncology products to Egypt's SEDICO, replacing a US$10.7 million import bill; in November 2026 the partners began technical preparations for first local production.

Parties: Sandoz (Switzerland) → SEDICO (Egypt)

Value
Undisclosed
Territory
Egypt
Therapeutic area
Oncology
Assets
Five oncology products (unnamed); Biosimilars (scope under discussion)
Announced
6 Mar 2025

Our analysis

Why this matters

Sandoz and SEDICO signed an agreement on 6 March 2025, witnessed by the Egyptian Drug Authority (EDA) at the Ministry of Health and Population, to localise five oncology products in Egypt through a full manufacturing technology transfer. The products cover chemotherapy, hormonal and targeted cancer treatments. According to the EDA, they have a market value in Egypt above EGP 371 million and an import bill of about US$10.7 million. The partnership grew out of an MoU first agreed in March 2023.

The deal moved forward in November 2026. Souq Al Dawaa reported on 7 November that SEDICO chairman Dr. Fathi Ibrahim and Dragos Florin Toma, head of Sandoz operations for Egypt and Libya, met to start the joint project, with technical preparations under way ahead of first local production. Biosimilars are also now in scope. No production start date has been given.

The full analysis is free to read with a work email on this page.

Source: Egyptian Drug Authority

More deals involving Sandoz or SEDICO

Latest deals

All MENA deals → · All technology transfer / localization deals → · Browse all emerging-market pharma deals →